$8.85
5.04%
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US23954D1090
Symbol
DAWN

Day One Biopharmaceuticals Inc Stock price

$8.85
+0.42 4.98% 1M
+2.12 31.50% 6M
-0.47 5.04% YTD
-3.86 30.37% 1Y
-12.67 58.88% 3Y
-17.04 65.82% 5Y
+7.80 742.86% 10Y
+7.80 742.86% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.47 5.04%
ISIN
US23954D1090
Symbol
DAWN
Industry

Key metrics

Basic
Market capitalization
$908.7m
Enterprise Value
$457.1m
Net debt
positive
Cash
$451.6m
Shares outstanding
102.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
6.8 | 6.0
EV/Sales
3.4 | 3.0
EV/FCF
negative
P/B
2.0
Financial Health
Equity Ratio
86.3%
Return on Equity
-19.0%
ROCE
-36.2%
ROIC
-341.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$133.7m | $151.5m
EBITDA
$-162.3m | $-124.0m
EBIT
$-165.6m | $-128.4m
Net Income
$-151.8m | $-106.7m
Free Cash Flow
$-124.9m
Growth (TTM | estimate)
Revenue
31.1% | 15.5%
EBITDA
22.8% | 42.5%
EBIT
21.7% | 40.9%
Net Income
-80.0% | -11.8%
Free Cash Flow
-16.3%
Margin (TTM | estimate)
Gross
89.4%
EBITDA
-121.4% | -81.8%
EBIT
-123.9%
Net
-113.5% | -70.4%
Free Cash Flow
-93.4%
More
EPS
$-1.5
FCF per Share
$-1.2
Short interest
13.5%
Employees
182
Rev per Employee
$720.0k
Show more

Is Day One Biopharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Day One Biopharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Day One Biopharmaceuticals Inc forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Day One Biopharmaceuticals Inc forecast:

Buy
87%
Hold
13%

Financial data from Day One Biopharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
134 134
31% 31%
100%
- Direct Costs 14 14
513% 513%
11%
120 120
20% 20%
89%
- Selling and Administrative Expenses 116 116
8% 8%
87%
- Research and Development Expense 169 169
17% 17%
126%
-162 -162
23% 23%
-121%
- Depreciation and Amortization 3.35 3.35
160% 160%
3%
EBIT (Operating Income) EBIT -166 -166
22% 22%
-124%
Net Profit -152 -152
80% 80%
-114%

In millions USD.

Don't miss a Thing! We will send you all news about Day One Biopharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Day One Biopharmaceuticals Inc Stock News

Positive
Seeking Alpha
16 days ago
Day One Biopharmaceuticals, Inc. is gaining momentum after Ojemda's strong Q3 launch, with revenues up 15% sequentially and full-year guidance raised to $145–$150m. DAWN's Ojemda is the only therapy specifically approved for PLGG, with a chance to become standard of care and ongoing Phase 3 front-line study. Strategic moves include acquiring Mersana Therapeutics for ADC pipeline expansion and a...
Neutral
GlobeNewsWire
19 days ago
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 44th Annual J.P.
Neutral
GlobeNewsWire
about one month ago
Updated data expands clinically meaningful results available from FIREFLY-1 pivotal trial  77% of patients who entered the treatment-free observation period following OJEMDA treatment remained off therapy for at least 12 months The median time to next treatment (TTNT) following initiation of OJEMDA exceeded 3.5 years    BRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceutic...
More Day One Biopharmaceuticals Inc News

Company Profile

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in South San Francisco, CA.

Head office United States
CEO Jeremy Bender
Employees 182
Founded 2018
Website dayonebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today